1. Kipps, T.J. et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3, 16096 (2017).
2. Fabbri, G. & Dalla-Favera, R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer 16 (2016).
3. Chiorazzi, N., Chen, S.S. & Rai, K.R. Chronic Lymphocytic Leukemia. Cold Spring Harb Perspect Med (2020).
4. Burger, J.A. & Gribben, J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Seminars in Cancer Biology 24, 71-81 (2014).
5. Ghia, P., Chiorazzi, N. & Stamatopoulos, K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. Journal of internal medicine 264, 549-562 (2008).
6. Munk Pedersen, I. & Reed, J. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45, 2365-2372 (2004).
7. Burger, J.A. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Semin Cancer Biol.
8. Agarwal, A. et al. Genetic and cytokine changes associated with symptomatic stages of CLL. Leuk Res (2014).
9. Patel, K. & Pagel, J.M. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep (2019).
10. Frustaci, A.M. et al. Duvelisib for the treatment of chronic lymphocytic leukemia. Expert opinion on pharmacotherapy 21, 1299-1309 (2020).
11. Lampson, B.L. & Brown, J.R. PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert opinion on investigational drugs 26, 1267-1279 (2017).
12. Peluso, M. et al. Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ. Blood 124, abstract 328 (2014).
13. Winkler, D.G. et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chemistry & biology 20, 1364-1374 (2013).
14. Hoellenriegel, J. et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118, 3603-3612 (2011).
15. De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539, 443-447 (2016).
16. Kaneda, M.M. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437-442 (2016).
17. Balakrishnan, K. et al. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia 29, 1811-1822 (2015).
18. Copiktra (duvelisib) [package insert]. Verastem, Inc. Needham, MA. http://www.verastem.com/pdf/prescribing-information.pdf (2018).
19. Flinn, I.W. et al. Duvelisib, a novel oral dual inhibitor of PI3K-delta,gamma, is clinically active in advanced hematologic malignancies. Blood 131, 877-887 (2018).
20. Imbruvica (ibrutinib) [package insert]. Pharmacyclics, Inc. Sunnyvale, CA. . https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205552s205029,210563s205004lbl.pdf (2019).
21. Gango, A. et al. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int. J. Cancer (2019).
22. Woyach, J.A. et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286-2294 (2014).
23. Zhang, S.Q., Smith, S.M., Zhang, S.Y. & Lynn Wang, Y. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br. J. Haematol. 170, 445-456 (2015).
24. Lampson, B.L.B., J. R. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia. . Expert Review of Hematology 11, 185-194 (2018).
25. Dong, S. et al. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. Blood 124, 3583-3586 (2014).
26. Chen, S.S. Method for generating a patient-derived xenograft model of CLL, in Chronic Lymphocytic Leukemia Methods and Protocols, Vol. Methods in Molecular Biology volume 1881. (ed. S.N. Malek) 165 (Humana Press, New York, NY; 2018).
27. Patten, P.E. et al. Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. JCI insight 1 (2016).
28. Chen, S.S. & Chiorazzi, N. Murine genetically engineered and human xenograft models of chronic lymphocytic leukemia. Seminars in hematology 51, 188-205 (2014).
29. Arlauckas, S.P. et al. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics 8, 5842-5854 (2018).
30. Ying, W., Cheruku, P.S., Bazer, F.W., Safe, S.H. & Zhou, B. Investigation of macrophage polarization using bone marrow derived macrophages. Journal of visualized experiments : JoVE (76). doi, 10.3791/50323 (2013).
31. Ten Hacken, E. & Burger, J.A. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochimica et biophysica acta 1863, 401-413 (2016).
32. van Attekum, M.H.A. et al. Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. Oncogene 36, 3651-3660 (2017).
33. Galletti, G. et al. Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. Cell reports 14, 1748-1760 (2016).
34. Damle, R.N. et al. B-CLL patients can be divided into two distinct clinical categories based on CD38 expression and Ig V gene mutation status. Blood 92, 431a (1998).
35. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94 (1999).
36. Mato, A.R. et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103, 1511-1517 (2018).
37. Byrd, J.C. et al. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine 369, 32-42 (2013).
38. Furman, R.R. et al. Ibrutinib Resistance in Chronic Lymphocytic Leukemia. New England Journal of Medicine 370, 2352-2354 (2014).
39. Woyach, J.A. et al. Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. New England Journal of Medicine 370, 2286-2294 (2014).
40. Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456 (2008).
41. Stephens, D.M. & Byrd, J.C. How we manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, blood-2018-2011-846808 (2019).
42. Quinquenel, A. et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 134, 641-644 (2019).
43. Fecteau, J.F. & Kipps, T.J. Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia. Front Biosci (Schol Ed) 4, 61-73 (2012).
44. Zhang, S. & Kipps, T.J. The pathogenesis of chronic lymphocytic leukemia. Annual review of pathology 9, 103-118 (2014).
45. Faia, K. et al. The phosphoinositide-3 kinase (PI3K)-delta,gamma inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PloS one 13, e0200725 (2018).
46. Sasaki, T. et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040-1046 (2000).
47. Rodrigues, D.A., Sagrillo, F.S. & Fraga, C.A.M. Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases. Pharmaceuticals (Basel) 12 (2019).
48. Flinn, I.W. et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood 132, 2446-2455 (2018).
49. Ali, A.Y. et al. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow. Br. J. Haematol. 185, 883-887 (2019).
50. Bilancio, A. et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 107, 642-650 (2006).
51. Martinelli, S. et al. Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia. Haematologica 103, e598-e601 (2018).
52. Bagnara, D. et al. Autologous human T cells and allogeneic antigen-presenting cells permit effective adoptive transfer of B-CLL cells into immune deficient mice. Blood in press (2009).
53. Roessner PM, S.M. T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease? . Leukemia 34, 2012-2024 (2020).
54. Palazzo, A. et al. The PI3Kdelta-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo. J. Immunol. 200, 2304-2312 (2018).
55. Horwitz, S.M. et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood 131, 888-898 (2018).
56. Sica, A. & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122, 787-795 (2012).
57. Long, M. et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Invest. 127, 3052-3064 (2017).
58. Parry, H.M. et al. Long-Term Ibrutinib Therapy Reverses CD8(+) T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia. Front. Immunol. 10, 2832 (2019).
59. Solman, I.G.B., L. K.; Hoh, H. Y.; Kipps, T. J.; Burger, J. A.; Barrientos, J. C.; O'Brien, S.; Mulligan, S. P.; Kay, N. E.; Hillmen, P.; Byrd, J. C.; Lal, I. D.; Dean, J. P. ; Mongan, A. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. . Leukemia Research, Epub (2020).
60. J. C. Barrientos, S.O.B., J. R. Brown, N. E. Kay, N. M. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, C. Pocock, T. Robak, S. J. Schuster, A. Schuh, D. Gill, A. Bloor, C. Dearden, C. Moreno, G. Cull, M. Hamblin, J. A. Jones, K. Eckert, I. G. Solman, S. Suzuki, E. Hsu, D. F. James, J. C. Byrd, P. Hillmen. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. . Clinical Lymphoma, Myeloma & Leukemia 18, 803-813 (2018).
61. Porcu, P. et al. Clinical Activity of Duvelisib (IPI-145), a Phosphoinositide-3-Kinase-δ,γ Inhibitor, in Patients Previously Treated with Ibrutinib. Blood 124, Abstract 3335 (2014).
62. Fais, F. et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 102, 1515-1525 (1998).
63. Evans, C.A. et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-gamma Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med. Chem. Lett. 7, 862-867 (2016).